E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults ≥ 50 years of age [YOA ] and immunocompromised adults ≥ 18 YOA.) |
|
E.1.1.1 | Medical condition in easily understood language |
Herpes Zoster (shingles) disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019974 |
E.1.2 | Term | Herpes zoster |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10019972 |
E.1.2 | Term | Herpes viral infections |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the vaccine response rate (VRR) to the HZ/su vaccine (based on the humoral immune response) one month after the last vaccine dose in the HZ/su-FLU-D-QIV co-administration group.
To demonstrate non-inferiority in terms of humoral immune response of two doses of the HZ/su vaccine when FLU-D-QIV vaccine is co-administered with the first HZ/su vaccine dose compared to two doses of HZ/su vaccine given alone, one month after the last vaccine dose.
To demonstrate non-inferiority (in terms of HI antibody Geometric mean titres(GMTs)) of one dose of FLU-D-QIV vaccine when co-administered with the first HZ/su vaccine dose compared to one dose of FLU-D-QIV vaccine given alone, for the four strains included in FLU-D-QIV vaccine, at Day 21 post vaccination. |
|
E.2.2 | Secondary objectives of the trial |
To demonstrate non-inferiority (in terms of HI antibody SCRs) of one dose of FLU-D-QIV vaccine when co-administered with the first HZ/su vaccine dose compared to one dose of FLU-D-QIV vaccine given alone,for the four strains included in FLU-D-QIV vaccine,at Day 21 post vaccination.
To assess the immunogenicity of FLU-D-QIV vaccine in terms of GMTs, Seroprotection Rate (SPR) at Days 0 and 21 and Seroconversion Rate (SCR) and Mean Geometric Increase (MGI) at Day 21. The assessment of SPR and SCR will be based on CBER’s criteria
To evaluate the safety and reactogenicity following administration of HZ/su and FLU-D-QIV vaccines,up to one month post last vaccination,and during the whole follow-up period. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
•A male or female aged 50 years or older, at the time of the first vaccination with the study vaccine(s).
•Written informed consent obtained from the subject.
•Female subjects of non-childbearing potential may be enrolled in the study.
Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
•Female subjects of childbearing potential may be enrolled in the study, if the subject:
-has practiced adequate contraception for 30 days prior to vaccination, and
-has a negative pregnancy test on the day of vaccination, and
-has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series. |
|
E.4 | Principal exclusion criteria |
•Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
•Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose (for corticosteroids, this will mean prednisone ≥ to 20 mg/day, or equivalent). A prednisone dose of < 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
•Administration or planned administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose of study vaccine(s) (HZ/su and/or FLU-D-QIV vaccines) and ending 30 days after the last dose of HZ/su vaccine.
•Administration of an influenza vaccine during the six months preceding entry into the study or planned administration up to the last blood sampling with the exception of the FLU-D-QIV vaccine given during this study.
•Administration of long-acting immune-modifying drugs (e.g. infliximab) within six months prior to the first vaccine dose or expected administration at any time during the study period.
•Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
•Previous vaccination against VZV or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
•History of HZ.
•Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., malignancy, HIV infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders).
•History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
•History of Guillain Barré syndrome.
•Hypersensitivity to latex.
•Acute disease and/or fever at the time of enrolment.
-Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C /100.4°F on rectal route. The preferred route for recording temperature in this study will be oral.
-Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
•Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
•Pregnant or lactating female.
•Female planning to become pregnant or planning to discontinue contraceptive precautions before 2 months after the last dose of study vaccine.
•Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.
•Any condition which, in the judgment of the investigator would make intramuscular injection unsafe. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
A.HZ/su humoral immunogenicity:
-Vaccine response for anti-gE humoral immunogenicity, as determined by enzyme-linked immunosorbent assay (ELISA), in subjects from the HZ/su-FLU-D-QIV Co-Ad group.
-Anti-gE antibody concentrations as determined by ELISA.
B.FLU-D-QIV humoral immunogenicity:
-Serum HI antibody titres against the four influenza vaccine strains will be used to calculate GMTs. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
A. at one month post-dose 2
B. at Day 21.
|
|
E.5.2 | Secondary end point(s) |
A.FLU-D-QIV humoral immune response:
Serum HI antibody titres against the four influenza vaccine strains will be used to calculate: Seropositivity rates, GMTs of HI antibody titres, SCR, MGI, SPR.
B.Occurrence of solicited local and general symptoms:
-Occurrence, intensity and duration of each solicited local symptom.
-Occurrence, intensity, duration and relationship to vaccination of each solicited general symptom.
C.Occurrence of unsolicited adverse events:
-Occurrence, intensity and relationship to vaccination of unsolicited AEs.
D.Occurrence of Serious Adverse Events (SAEs):
-Occurrence and relationship to vaccination of all SAEs.
E.Occurrence of potential Immune-Mediated Diseases (pIMDs):
-Occurrence and relationship to vaccination of any pIMDs. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
A. SPR, GMT and SPR on Days 0 and 21; SCR and MGI on Day 21
B. within 7 days (Days 0-6) after each vaccination.
C. during 30 days (Days 0-29) after each vaccination.
D. and E.from first vaccination up to study end.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Separate vaccination schedule |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |